Show simple item record

dc.contributor.authorMustafayeva, Leyla
dc.contributor.authorUĞURLU, SERDAL
dc.contributor.authorCelik, Yeliz
dc.contributor.authorAyla, Ali Yagiz
dc.contributor.authorAK, TÜMAY
dc.date.accessioned2023-10-10T11:44:25Z
dc.date.available2023-10-10T11:44:25Z
dc.date.issued2023
dc.identifier.citationAK T., Mustafayeva L., Celik Y., Ayla A. Y., UĞURLU S., "When to start secukinumab treatment in patients with axial spondyloarthropathy: Before or after anti-TNFot treatment?", REUMATOLOGIA CLINICA, cilt.19, sa.4, ss.175-179, 2023
dc.identifier.issn1699-258X
dc.identifier.othervv_1032021
dc.identifier.otherav_19a1c3e0-5179-475c-b70d-64c7cb48bfe8
dc.identifier.urihttp://hdl.handle.net/20.500.12627/189884
dc.identifier.urihttps://doi.org/10.1016/j.reuma.2022.03.007
dc.description.abstractIntroduction and objectives: This study aimed to evaluate the efficacy of secukinumab (SEC) in axial spondyloarthropathy (axSpA) in anti-TNFot naive and anti-TNFot experienced patients. It also focused on the duration of SEC treatment and its side effects.Patients and methods: The patients with axSpA treated with SEC and followed up in our outpatient clinic from May 2018 through October 2021 were included in this study. All patients in the study also fulfilled the ASAS classification criteria for axSpA. Patients were separated into two groups according to whether they received prior anti-TNFot therapy. While anti-TNFot naive patients comprised group 1, anti-TNFot experienced patients were included in group 2. Pre-and post-treatment BASDAI scores were reported and compared.Results: Eighty-four axSpA patients (42 men; duration of the disease: 86.86 +/- 65.35 months in group 1 and 160.65 +/- 97.4 months in group 2) were treated with SEC. 45.5% of anti-TNFot naive patients and 56.5% of anti-TNFot experienced patients were still on SEC therapy in October 2021. Duration of SEC treatment was 12.5 +/- 7.9 months in group 1 and 17.19 +/- 12 months in group 2 (p = 0.098). The differences between pre-and post-treatment BASDAI scores were statistically significant in both groups (p < 0.001). While patients in group 1 did not develop any adverse effects, three patients in group 2 experienced alopecia, uveitis, and recurrent pneumonia after SEC treatment.Conclusion: Our study's efficacy and safety data on the use of SEC were reassuring in both anti-TNFot naive and anti-TNFot experienced patients. However, further studies are still needed to determine the appropriate timing to begin SEC treatment.(c) 2022 Elsevier Espan similar to a, S.L.U. and Sociedad Espan similar to ola de Reumatologi ' a y Colegio Mexicano de Reumatologi ' a. All rights reserved.
dc.language.isoeng
dc.subjectRomatoloji
dc.subjectİmmünoloji ve Romatoloji
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectROMATOLOJİ
dc.titleWhen to start secukinumab treatment in patients with axial spondyloarthropathy: Before or after anti-TNFot treatment?
dc.typeMakale
dc.relation.journalREUMATOLOGIA CLINICA
dc.contributor.departmentİstanbul Üniversitesi-Cerrahpaşa , Cerrahpaşa Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü
dc.identifier.volume19
dc.identifier.issue4
dc.identifier.startpage175
dc.identifier.endpage179
dc.contributor.firstauthorID4312222


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record